Hereditary transthyretin amyloidosis (ATTRv) is a rare genetic disorder caused by the deposition of misfolded transthyretin (TTR) proteins, leading to widespread organ dysfunction.1 Advances in understanding the pathogenesis of ATTRv have paved the way for novel therapeutic strategies beyond traditi